Elite Pharmaceuticals, Inc. (ELTP)
0.2286
0.00 (0.00%)
USD |
OTCM |
Oct 02, 16:00
Elite Pharmaceuticals Gross Profit Margin (Quarterly) : 40.61% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 40.61% |
| March 31, 2026 | 50.07% |
| December 31, 2025 | 39.78% |
| September 30, 2025 | 37.66% |
| June 30, 2025 | 66.73% |
| March 31, 2025 | 52.77% |
| December 31, 2024 | 39.59% |
| September 30, 2024 | 41.19% |
| June 30, 2024 | 42.81% |
| March 31, 2024 | 43.11% |
| December 31, 2023 | 43.10% |
| September 30, 2023 | 43.23% |
| June 30, 2023 | 49.25% |
| March 31, 2023 | 36.01% |
| December 31, 2022 | 49.75% |
| September 30, 2022 | 40.82% |
| June 30, 2022 | 48.24% |
| March 31, 2022 | 40.77% |
| December 31, 2021 | 41.46% |
| September 30, 2021 | 40.53% |
| June 30, 2021 | 45.92% |
| March 31, 2021 | 35.10% |
| December 31, 2020 | 50.85% |
| September 30, 2020 | 44.42% |
| June 30, 2020 | 35.14% |
| Date | Value |
|---|---|
| March 31, 2020 | 43.13% |
| December 31, 2019 | 50.81% |
| September 30, 2019 | 21.51% |
| June 30, 2019 | 28.92% |
| March 31, 2019 | 16.21% |
| December 31, 2018 | 22.33% |
| September 30, 2018 | 33.31% |
| June 30, 2018 | 17.88% |
| March 31, 2018 | 22.31% |
| December 31, 2017 | 43.72% |
| September 30, 2017 | 61.68% |
| June 30, 2017 | 39.99% |
| March 31, 2017 | 68.13% |
| December 31, 2016 | 25.01% |
| September 30, 2016 | 30.30% |
| June 30, 2016 | 33.66% |
| March 31, 2016 | 76.71% |
| December 31, 2015 | 54.31% |
| September 30, 2015 | 41.45% |
| June 30, 2015 | 37.36% |
| March 31, 2015 | 26.78% |
| December 31, 2014 | 33.04% |
| September 30, 2014 | 23.71% |
| June 30, 2014 | 20.60% |
| March 31, 2014 | -1.78% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Daré Bioscience, Inc. | -294.5% |
| Eton Pharmaceuticals, Inc. | 67.61% |
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
| Veru, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 72.04% |
| Return on Assets | 44.66% |
| Return on Invested Capital | 66.87% |
| Profit Margin (Quarterly) | 18.27% |
| Operating Margin (Quarterly) | 23.27% |
| Return on Net Operating Assets | 63.98% |